Seppic discloses SUBLIGANA™, an anti-imperfection active ingredient for blemished and acne-prone skin

Seppic launches SUBLIGANA™, an active ingredient for anti-imperfection, anti-spot & flawless-looking complexion concepts related to oxidative stress, designed by Serdex a subsidiary of SEPPIC since January 2017.

Acne is affecting about 80% of persons at some point in their lives\(^1\). New studies have shown that an increased cutaneous and systemic oxidative stress is involved \(^2\).

SUBLIGANA™ is a titrated extract of *Harungana madagascariensis* originated from the center and east of Madagascar. By forming a physical and a repulsive barrier, *Harungana madagascariensis* protects primary forest areas from attacks and is capable of restoring degraded landscapes. It is considered by botanists as a "forest Guard". Traditionally, leaf decoctions are used against asthma and skin disorders and leaf juice is used for wound healing.

SUBLIGANA™ addresses blemished skin and acne-prone skin. An *in-use test on teenagers presenting acne-prone skin* showed a significant whiteheads reduction versus placebo after 28 days. SUBLIGANA™ mechanism of action combines soothing effect (lipase inhibition, IL-10 and IL-12 regulation), antioxidant effect (protection against lipid peroxidation) and efficacy against *Propionibacterium acnes*.

*Harungana madagascariensis* leaves are collected under good collecting practices in the high plateaus area in Madagascar to ensure a repeatable and reliable phytochemical composition. Overall, Serdex is committed to the principles of the Nagoya Protocol and implements practices for *fair and equitable sharing of benefits*.

SUBLIGANA™ is China compliant (IECIC listed) and Cosmos compliant.

**Virginie Anchartéchahar**, R&D Manager for Serdex confirms: "*On the basis of scientific results, we have developed an original mechanism of action focusing on soothing and anti-oxidant effect to address acne-prone skin.*"

**References**
2: Bowe et al.. Clinical implications of lipid peroxidation in acne vulgaris old wine in new bottles, Lipids in Health and Disease 2010.

---

**Seppic in brief**
A subsidiary of the Air Liquide group in the Healthcare business, Seppic creates and markets a wide range of specialty ingredients for health and beauty. Present in 100 countries through its subsidiaries and its network of distributors, Seppic employs 700 people worldwide, including 100 employees dedicated to innovation. [www.seppic.com](http://www.seppic.com)

**Serdex**
A subsidiary of Seppic since January 2017, Serdex is specialized in the development and manufacturing of highly purified and substantiated active ingredients extracted from Malagasy plants and dedicated to the cosmetic and pharmaceutical markets. They are issued from a long term partnership with local Malagasy suppliers committed to the fair and equitable sharing of benefits under Nagoya Protocol.

**Air Liquide Healthcare**
supplies medical gases, home healthcare services, hygiene products, medical equipment and specialty ingredients. In 2016, it served over 15,000 hospitals and 1.4 million patients at home throughout the world. The Group’s Healthcare business reached € 3,111 million in revenues in 2016, with the support of its 15,000 employees.

[www.seppic.com](http://www.seppic.com)
Follow us on [Twitter](https://twitter.com/seppic)
The world leader in gases, technologies and services for Industry and Health, Air Liquide is present in 80 countries with approximately 67,000 employees and serves more than 3 million customers and patients. Oxygen, nitrogen and hydrogen are essential small molecules for life, matter and energy. They embody Air Liquide's scientific territory and have been at the core of the company's activities since its creation in 1902.

Air Liquide's ambition is to lead its industry, deliver long term performance and contribute to sustainability. The company's customer-centric transformation strategy aims at profitable growth over the long term. It relies on operational excellence, selective investments, open innovation and a network organization implemented by the Group worldwide. Through the commitment and inventiveness of its people, Air Liquide leverages energy and environment transition, changes in healthcare and digitization, and delivers greater value to all its stakeholders.

Air Liquide’s revenue amounted to € 18.1 billion in 2016 and its solutions that protect life and the environment represented more than 40% of sales. Air Liquide is listed on the Euronext Paris stock exchange (compartment A) and belongs to the CAC 40, EURO STOXX 50 and FTSE4Good indexes.